Reversin 121
Also known as: P-gp inhibitor peptide 121, Reversin-121
Source Reversin 121 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Reversin 121 is a short cyclic peptide identified as a potent modulator of P-glycoprotein (MDR1/ABCB1). It was discovered through combinatorial peptide library screening and demonstrated ability to sensitize multidrug-resistant cancer cell lines to chemotherapeutic agents such as doxorubicin and vinblastine by blocking P-gp efflux activity. It remains a research tool compound with no clinical development reported.
Mechanism of Action
Inhibits P-glycoprotein (P-gp/ABCB1)-mediated drug efflux by binding to the transporter, thereby reversing multidrug resistance (MDR) in cancer cells and increasing intracellular accumulation of cytotoxic agents.
Routes of Administration
Goals & Uses
- Reversal of multidrug resistance in cancerOncology / Pharmacology ResearchLow
- Increased intracellular accumulation of chemotherapeuticsDrug Delivery / Pharmacokinetics ResearchLow
Contraindications
- Human clinical useRegulatoryHigh
Adverse Effects
- Unknown systemic toxicityGeneralUnknown
Drug Interactions
- P-glycoprotein substrates (e.g., doxorubicin, vinblastine, paclitaxel)High
Population Constraints
- General human populationRegulatory/safetyAbsolute
Regulatory Status
- European UnionUnapprovedNo EMA filing; research use only.
- United StatesUnapprovedNo IND or regulatory filing; research use only.
- United KingdomUnapprovedNo MHRA filing; research use only.
No regulatory filings identified in any jurisdiction. Strictly a research/in vitro tool compound.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Reversin 121?
Reversin 121 is a short cyclic peptide identified as a potent modulator of P-glycoprotein (MDR1/ABCB1). It was discovered through combinatorial peptide library screening and demonstrated ability to sensitize multidrug-resistant cancer cell lines to chemotherapeutic agents such as doxorubicin and vinblastine by blocking P-gp efflux activity. It remains a research tool compound with no clinical development reported.
What is Reversin 121 used for?
Reversin 121 is educationally associated with: Reversal of multidrug resistance in cancer, Increased intracellular accumulation of chemotherapeutics. Educational only — not medical advice.
How is Reversin 121 administered?
Recorded routes of administration: In Vitro.
What are the potential side effects of Reversin 121?
Reported adverse effects include: Unknown systemic toxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid Reversin 121?
Recorded contraindications: Human clinical use. Consult a qualified clinician before use.